Form 8-K - Current report:
SEC Accession No. 0001213900-25-002846
Filing Date
2025-01-13
Accepted
2025-01-13 08:15:07
Documents
14
Period of Report
2025-01-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0227474-8k_aditxt.htm   iXBRL 8-K 30362
2 PRESS RELEASE DATED JANUARY 13, 2025 ea022747401ex99-1_aditxt.htm EX-99.1 10122
  Complete submission text file 0001213900-25-002846.txt   221104

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE adtx-20250113.xsd EX-101.SCH 3009
4 XBRL LABEL FILE adtx-20250113_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE adtx-20250113_pre.xml EX-101.PRE 22355
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0227474-8k_aditxt_htm.xml XML 3784
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39336 | Film No.: 25524933
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)